KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $145000.0.

  • Arbutus Biopharma's Change in Accured Expenses rose 10406.85% to $145000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year decrease of 2780.73%. This contributed to the annual value of -$2.7 million for FY2024, which is 5298.71% up from last year.
  • According to the latest figures from Q3 2025, Arbutus Biopharma's Change in Accured Expenses is $145000.0, which was up 10406.85% from -$7.6 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Change in Accured Expenses ranged from a high of $4.5 million in Q1 2025 and a low of -$7.6 million during Q2 2025
  • Moreover, its 5-year median value for Change in Accured Expenses was $145000.0 (2025), whereas its average is -$223631.6.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 59068.63% in 2023, then plummeted by 45604.4% in 2024.
  • Arbutus Biopharma's Change in Accured Expenses (Quarter) stood at $1.3 million in 2021, then skyrocketed by 183.56% to $3.8 million in 2022, then crashed by 87.63% to $465000.0 in 2023, then plummeted by 95.7% to $20000.0 in 2024, then surged by 625.0% to $145000.0 in 2025.
  • Its last three reported values are $145000.0 in Q3 2025, -$7.6 million for Q2 2025, and $4.5 million during Q1 2025.